1. Home
  2. ADAP vs BKKT Comparison

ADAP vs BKKT Comparison

Compare ADAP & BKKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • BKKT
  • Stock Information
  • Founded
  • ADAP 2008
  • BKKT 2018
  • Country
  • ADAP United Kingdom
  • BKKT United States
  • Employees
  • ADAP 506
  • BKKT N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • BKKT Computer Software: Prepackaged Software
  • Sector
  • ADAP Health Care
  • BKKT Technology
  • Exchange
  • ADAP Nasdaq
  • BKKT Nasdaq
  • Market Cap
  • ADAP 75.5M
  • BKKT 63.5M
  • IPO Year
  • ADAP 2015
  • BKKT N/A
  • Fundamental
  • Price
  • ADAP $0.29
  • BKKT $10.04
  • Analyst Decision
  • ADAP Strong Buy
  • BKKT
  • Analyst Count
  • ADAP 5
  • BKKT 0
  • Target Price
  • ADAP $1.83
  • BKKT N/A
  • AVG Volume (30 Days)
  • ADAP 777.8K
  • BKKT 195.8K
  • Earning Date
  • ADAP 05-13-2025
  • BKKT 05-12-2025
  • Dividend Yield
  • ADAP N/A
  • BKKT N/A
  • EPS Growth
  • ADAP N/A
  • BKKT N/A
  • EPS
  • ADAP N/A
  • BKKT N/A
  • Revenue
  • ADAP $178,032,000.00
  • BKKT $3,490,220,000.00
  • Revenue This Year
  • ADAP N/A
  • BKKT N/A
  • Revenue Next Year
  • ADAP $69.81
  • BKKT N/A
  • P/E Ratio
  • ADAP N/A
  • BKKT N/A
  • Revenue Growth
  • ADAP 195.34
  • BKKT 347.39
  • 52 Week Low
  • ADAP $0.20
  • BKKT $6.60
  • 52 Week High
  • ADAP $1.48
  • BKKT $37.21
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 51.38
  • BKKT 52.62
  • Support Level
  • ADAP $0.30
  • BKKT $8.76
  • Resistance Level
  • ADAP $0.32
  • BKKT $10.92
  • Average True Range (ATR)
  • ADAP 0.02
  • BKKT 0.74
  • MACD
  • ADAP 0.01
  • BKKT 0.17
  • Stochastic Oscillator
  • ADAP 67.44
  • BKKT 61.37

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About BKKT Bakkt Holdings Inc.

Bakkt Holdings Inc operates technology that connects the digital economy by offering a platform for crypto and redeeming loyalty points. Its institutional-grade technology platform provides a custody solution that caters to more experienced market participants to store crypto and provides consumers, businesses, and institutions with the ability to buy, sell, and store crypto in a simple, intuitive digital experience accessed via application programming interfaces (APIs) or embedded web experience and Loyalty offers a full spectrum of content that clients can make available to its customers when redeeming loyalty currencies. It generates revenue in the form of Subscription and service and Transaction revenue.

Share on Social Networks: